Novacyt: Settlement and Redemption of All Outstanding Yorkville Convertible Bonds

Removes potentially dilutive instrument

Strengthened balance sheet supports future growth

PARIS & CAMBRIDGE, England--()--Regulatory News:

Novacyt (BOURSE:ALNOV)(EURONEXT GROWTH:ALNOV)(AIM:NCYT), an international specialist in clinical diagnostics, today announces the full redemption and settlement of the 40 pending convertible bonds (the “OCA”) under the Yorkville facility agreement, with immediate effect.

In July 2015, Novacyt executed a flexible bond financing instrument with Yorkville for a maximum of €5.0m over three years to support the planned growth of the Group. The Company has drawn down €3.75m (i.e. 15 of the original 20 tranches) up to the date of admission to AIM with €0.4m of this remaining unconverted into equity. The Company has agreed to make a full and final repayment of €0.4m to Yorkville to redeem all these remaining outstanding convertible bonds.

Furthermore, the Company confirms it will make no further drawdowns against the Yorkville facility agreement.

Anthony Dyer, Chief Financial Officer of Novacyt, commented:

“We would like to thank Yorkville for their support and flexibility during a transformational stage in the Company’s evolution. The funds raised as part of the dual listing on AIM have strengthened our balance sheet, allowing us to redeem a potentially dilutive convertible instrument. In addition, this strengthened balance sheet supports the Company along its pathway to sustainable profitability and positive cash flow generation.”

About Novacyt Group

The Novacyt Group is a rapidly growing, international diagnostics group with a growing portfolio of cancer and infectious disease products and services. Through its proprietary technology platform, NOVAPrep®, and molecular platform, genesig®, Novacyt is able to provide an extensive range of oncology and infectious disease diagnostic products across an extensive international distributor network. The Group has diversified sales from diagnostic reagents used in oncology, microbiology, haematology and serology markets, and its global customers and partners include major corporates.

For more information please refer to the website: www.novacyt.com

Contacts

Novacyt SA
Graham Mullis, Chief Executive Officer
Anthony Dyer, Chief Financial Officer
+44 (0)1223 395472
or
Stifel Nicolaus Europe Limited (Nominated Advisor and Joint Broker)
Jonathan Senior / Fred Walsh / Ben Maddison
+44 (0)20 7610 7600
or
WG Partners (Joint Broker)
Nigel Birks / Claes Spång
+44 (0) 203 705 9330
or
International
Brett Pollard / Victoria Foster Mitchell
FTI Consulting
+44 (0)20 3727 1000
brett.pollard@fticonsulting.com / victoria.fostermitchell@fticonsulting.com
or
France
Arnaud de Cheffontaines / Astrid Villette
FTI Consulting
+33 (0)147 03 69 47 / +33 (0)147 03 69 51
arnaud.decheffontaines@fticonsulting.com / astrid.villette@fticonsulting.com

Contacts

Novacyt SA
Graham Mullis, Chief Executive Officer
Anthony Dyer, Chief Financial Officer
+44 (0)1223 395472
or
Stifel Nicolaus Europe Limited (Nominated Advisor and Joint Broker)
Jonathan Senior / Fred Walsh / Ben Maddison
+44 (0)20 7610 7600
or
WG Partners (Joint Broker)
Nigel Birks / Claes Spång
+44 (0) 203 705 9330
or
International
Brett Pollard / Victoria Foster Mitchell
FTI Consulting
+44 (0)20 3727 1000
brett.pollard@fticonsulting.com / victoria.fostermitchell@fticonsulting.com
or
France
Arnaud de Cheffontaines / Astrid Villette
FTI Consulting
+33 (0)147 03 69 47 / +33 (0)147 03 69 51
arnaud.decheffontaines@fticonsulting.com / astrid.villette@fticonsulting.com